Porcine rotavirus g1 strain and application thereof

Abstract

The application discloses a porcine rotavirus G1 type strain and application thereof. The application obtains a porcine rotavirus G1 type NM2507 strain from porcine intestinal tissue and through passage purification, and the microorganism preservation number of the strain is CGMCC No. 47090. The isolated strain can stably proliferate on a passage cell and produce a typical cytopathic effect. The porcine rotavirus G1 type isolated strain has excellent immunogenicity; a vaccine prepared by using the isolated strain can induce piglets to produce high-level neutralizing antibodies; meanwhile, an ELISA kit prepared by using the isolated strain can better detect porcine rotavirus G1 type antibodies in serum.

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to an isolated and purified porcine rotavirus G1 strain and its applications. Background Technology

[0002] Rotavirus (RV) belongs to the family Reoviridae and the genus Rotavirus. It resembles a wheel in shape, exhibiting icosahedral symmetry. Its central core is composed of nucleic acid and is densely hexagonal in shape, lacking an envelope. This virus is an important intestinal pathogen causing diarrhea in various newborn and young animals, and is also a common cause of gastroenteritis in suckling and weaned piglets.

[0003] Porcine rotavirus (PoRV) is a segmented double-stranded RNA virus. Its genome primarily encodes six structural proteins (VP1, VP2, VP3, VP4, VP6, and VP7) and six non-structural proteins (NSP1, NSP2, NSP3, NSP4, NSP5, and NSP6). The viral particle consists of three capsid proteins. The innermost layer is composed of VP2 and small amounts of VP1 and VP3 proteins, which together encapsulate the viral genomic RNA and are essential proteins for viral gene transcription and replication. The surface of PoRV viral particles contains three antigenic proteins: serogroup antigens, neutralizing antigens, and hemagglutinin antigens. The serogroup antigens are associated with multiple structural proteins and are mainly determined by the inner capsid protein VP6, which is the central nucleocapsid protein, accounting for 51% of the viral structural proteins. It is highly conserved and is an important antigen for clinical detection. Based on its VP6 antigen, rotavirus can be classified into seven serogroups: A, B, C, D, E, F, and G. Epidemiological surveys show that rotaviruses causing porcine diarrhea are most commonly found in serogroup A. The neutralizing antigen is primarily determined by the capsid glycoprotein VP7, forming the smooth surface of the virus; the hemagglutinin antigen is determined by the capsid protein VP4, forming the spike-like peak of the viral particle. VP7 and VP4 are the main determinants of viral serotypes and play a crucial role in pathogen detection, the production of neutralizing antibodies, and immune protection. Based on the antigenic characteristics of these two proteins, PoRV can be classified into two serotypes: G and P.

[0004] PoRV is a major intestinal pathogen causing diarrhea in suckling and weaned piglets. It was first reported in the UK in 1974, and in my country, it was first isolated from the feces of diarrheal piglets in 1981. The disease is widespread and has a high morbidity rate, prevalent in my country's pig farming industry, particularly in intensive pig farms. The incubation period for infected piglets is very short, with symptoms typically appearing within about one day. Piglets often exhibit lethargy, reduced activity, vomiting, and a significant decrease in feed intake. In the later stages of the disease, piglets develop severe diarrhea or dysentery; the stool is often yellow, but in severe cases it can be dark red. Affected piglets become severely dehydrated, emaciated, and grow slowly. If mixed or secondary infections occur with other pathogens, the mortality rate of piglets can reach 100%, seriously affecting the healthy development of my country's pig farming industry and causing severe economic losses to the livestock sector. In recent years, an increasing number of piglets have died from rotavirus infection. Adult pigs and breeding pigs are often asymptomatic carriers. Once infected with rotavirus, it will seriously affect the growth and development of pigs. Even healthy adult pigs will stop growing, leading to a significant increase in the culling rate of pig farms.

[0005] Currently, there is no specific drug treatment for this disease, making the development of effective drugs or vaccines for prevention and control crucial. Vaccination is the most effective prevention and control measure. Therefore, selecting an ideal strain and developing the best viral replication method are essential for the development of a PoRV vaccine.

[0006] Currently, PoRV G1 is showing an epidemic trend in some regions of my country, causing certain harm and economic losses to the aquaculture industry. However, traditional methods of isolating and scaling up PoRV culture present certain difficulties, and the viral titers are generally low. There are currently no PoRV G1 vaccine products on the market with particularly ideal efficacy. Research on PoRV vaccines and diagnostic methods is also relatively limited. Timely development of highly effective vaccines and diagnostic kits is of great significance for the prevention and control of this disease. Summary of the Invention

[0007] The purpose of this invention is to provide a porcine rotavirus G1 strain and its VP7 gene sequence, as well as the application of an inactivated vaccine prepared based on the isolate in the prevention and control of porcine rotavirus G1 disease.

[0008] To achieve the objectives of this invention, the technical solution is as follows: In a first aspect, the present invention provides a porcine rotavirus (PoRV) G1 strain and its VP7 gene sequence.

[0009] This invention involves inoculating MARC-145 or MA104 cells with a homogenized extract of porcine intestinal tissue from a pig farm in Inner Mongolia. After cell passage, purification, and identification, a porcine rotavirus G1 strain, named NM2507, was obtained. This strain exhibits stable proliferation in cells, and the quantitative fluorescence assay for porcine rotavirus showed a CT value of up to 15 and a TCID value of [missing value]. 50 Up to 1.0 × 10 8 TCID 50 / m1, deposited on December 9, 2025, at the China General Microbiological Culture Collection Center (Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC No. 47090. This invention provides the VP7 gene sequence of a porcine rotavirus G1 type isolate, as shown in SEQ ID No. 1.

[0010] Secondly, the present invention provides a biological product containing the porcine rotavirus G1 strain, the biological product being used for the prevention or diagnosis of porcine rotavirus G1 disease.

[0011] The biological product may be a vaccine or a diagnostic reagent.

[0012] The vaccine mentioned is either a live vaccine or an inactivated vaccine.

[0013] This invention provides an inactivated vaccine comprising an isolated porcine rotavirus G1 strain. The inactivated vaccine is prepared by passage of porcine rotavirus G1 strain NM2507 into MARC-145 cells, harvesting the viral fluid, determining the viral titer, and then mixing it with an adjuvant at a 1:1 weight ratio. Available adjuvants include a self-made gelatinous aqueous adjuvant from China Animal Husbandry Industry Co., Ltd., 201VG from Sepik Pharmaceutical Co., Ltd., and conventional aluminum adjuvants.

[0014] The inactivated vaccine antigen content is no less than 1×10⁻⁶ per dose. 7 TCID 50 / ml, the immunization route is intramuscular injection or oral administration, preferably intramuscular injection.

[0015] The reagent provided by this invention can be an ELISA kit containing the isolated porcine rotavirus G1 strain, which can effectively detect antibodies in serum.

[0016] Thirdly, the present invention also provides the use of the porcine rotavirus G1 strain in the preparation of a vaccine for the prevention of viral diseases caused by porcine rotavirus G1; and the use of the porcine rotavirus G1 strain in the preparation of a reagent for the diagnosis of viral diseases caused by porcine rotavirus G1.

[0017] The beneficial effects of this invention are as follows: The porcine rotavirus G1 strain obtained by this invention proliferates rapidly and with a high titer (up to 1.0 × 10⁻⁶) in susceptible cells (MARC-145 or MA104 cell lines). 8 TCID 50 / m1; The porcine rotavirus G1 strain of this invention has low pathogenicity, using 1×10 7 TCID 50 Oral challenge with / m1 virus solution to weaned piglets, followed by continuous observation for 10 days, showed no clinical symptoms such as fever or diarrhea, and all piglets survived. The inactivated vaccine prepared using the strain of this invention exhibits good immunogenicity and can induce high levels of neutralizing antibodies in piglets, providing important biological material for the effective prevention and control of porcine rotavirus G1 disease.

[0018] Currently, there are no commercially available ELISA kits for detecting porcine rotavirus G1. Therefore, establishing a serum antibody detection method is crucial for screening negative pigs. ELISA is characterized by high sensitivity, good specificity, and the ability to be performed in batches, making it convenient for clinical application. This invention provides an ELISA kit containing the isolated porcine rotavirus G1 strain, which can effectively detect porcine rotavirus G1 antibodies in serum, providing an important foundation for the effective detection of this disease.

[0019] Based on this, other biological products containing the porcine rotavirus G1 strain described in this invention for the prevention and diagnosis of porcine rotavirus G1 disease also fall within the scope of protection of this invention.

[0020] In 2025, this study isolated and purified a porcine rotavirus G1 strain, named NM2507, from intestinal tissue of pigs at a pig farm in Inner Mongolia. This isolate exhibited good proliferation in passaged cells, showed no significant pathogenicity in piglets, and demonstrated excellent immunogenicity, inducing high levels of neutralizing antibodies in piglets, thus laying a solid foundation for the effective control of porcine rotavirus G1. Furthermore, an ELISA kit prepared using this isolate effectively detected porcine rotavirus G1 antibodies in serum, providing a technical basis for the effective diagnosis of porcine rotavirus G1. Attached Figure Description

[0021] Figure 1 The images show cytopathic effects (CPE) of porcine rotavirus G1 isolate cultured on MA104 adherent cells. In the images, A represents the cytopathic effect (CPE) of porcine rotavirus G1 isolate on MA104 cells, and B represents the normal MA104 cell control (mock).

[0022] Preservation of biological materials Accession number: CGMCC No. 47090 Name: NM2507 Classification and nomenclature: Porcine rotavirus Preservation Institution: China General Microbiological Culture Collection Center (CGMCC) Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing Preservation period: December 9, 2025 Survival status: Yes. Detailed Implementation

[0023] Unless otherwise specified, the methods described in the following embodiments are conventional methods.

[0024] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the reagents used are all commercially available products.

[0025] Example 1: Isolation of porcine rotavirus G1 strain 1. Collection and processing of intestinal tissue Collect pig intestinal tissue, cut it into small pieces, add 10 times the volume of DMEM medium containing 500 units of double antibiotics and grind it. Centrifuge at 12,000 rpm for 5 min at 4℃, collect the supernatant of the grinding liquid, and freeze it at -80℃ for later use.

[0026] 2. Detection of pathogens in intestinal tissue Take 200 μL of the supernatant from the above-mentioned homogenate and extract nucleic acids using the DNA / RNA extraction kit and reverse transcription kit from Beijing TransGen Biotech Co., Ltd., following the manufacturer's instructions. Then, perform PCR detection using primers for classical swine fever virus (CSFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine pseudorabies virus (PRV), porcine circovirus type 2 / 3 (PCV2 / PCV3), porcine parvovirus (PPV), transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), porcine rotavirus (PoRV), and porcine deltacoronavirus (PDCoV). The results showed that the homogenate sample was positive for porcine rotavirus, while other pathogens were negative.

[0027] 3. Isolation of porcine rotavirus G1 strain In 2025, intestinal tissue was collected from an infected pig farm in Inner Mongolia, and RT-PCR testing confirmed positive for porcine rotavirus. Pigs in the infected farm exhibited clinical symptoms such as diarrhea. The collected intestinal tissue was inoculated into MARC-145 cells. After 1 hour of incubation, the incubation medium was discarded, and the cells were maintained in serum-free DMEM containing 5 μg / mL trypsin. 72 hours after inoculation, cells showed shrinkage, syncytial aggregation, and a small amount of detachment, while normal cells showed no cytopathic effects. Cell cultures were harvested 5 days after inoculation and passaged three times consecutively in MARC-145 cells. The fourth passage was inoculated into MA104 cells. After 16 hours, cells showed significant aggregation, shrinkage, and a small amount of detachment. Virus was harvested 20 hours after inoculation, and the cells were passaged three times consecutively in MA104 cells, consistently showing cytopathic effects (CPE).

[0028] The sixth-generation product underwent nucleic acid extraction and reverse transcription, and was identified as porcine rotavirus by PCR. The target band was purified by gel extraction and then sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing to obtain the porcine rotavirus VP7 genome sequence, as shown in SEQ ID No. 1. The obtained porcine rotavirus VP7 genome nucleic acid sequence was compared online with NCBI Blast, and the highest homology with the existing porcine rotavirus G1 strain sequence was only 96.77% (online comparison URL: https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). Therefore, this strain was identified as a novel porcine rotavirus G1 strain.

[0029] The isolated virus was passaged and propagated in MA104 adherent cells. The porcine rotavirus G1 strain cultured in the 6th generation adherent cells was inoculated into MA104 adherent cells at a ratio of 0.2%. Fifteen hours after inoculation, aggregated and fused cytopathic effects appeared in the cells, while normal cells showed no obvious cytopathic effects. The cell culture was harvested after 18 hours. The porcine rotavirus G1 strain was further passaged to the 7th generation. After 15 hours of culture, obvious cytopathic effects were observed. After positive identification, a porcine rotavirus G1 strain was obtained through expanded culture, named NM2507, and classified as porcine rotavirus. Porcine rotavirus G1 strain NM2507 was deposited on December 9, 2025, at the China General Microbiological Culture Collection Center (Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC No. 47090.

[0030] When porcine rotavirus G1 strain is inoculated into MA104 adherent cells and cultured, typical cytopathic effects appear after 15-18 hours, such as... Figure 1 As shown. When the cytopathic effect reached approximately 90%, the culture was harvested, subjected to one freeze-thaw cycle, and the viral titer was determined to be 1.0 × 10⁻⁶ according to the Reed & Muench method.8 TCID 50 / ml.

[0031] Example 2: Pathogenicity test of porcine rotavirus G1 strain NM2507 Six 30-day-old piglets that were negative for porcine rotavirus pathogen and antibodies were randomly divided into two groups of three piglets each. The experimental group underwent oral challenge, with each piglet inoculated with 2 mL of 10... 7.0 TCID 50 F7 passaged virus solution; in the control group, each pig was orally inoculated with an equal volume of sterile PBS solution. The pigs' condition was observed daily, and rectal temperature was measured and recorded.

[0032] After 10 days of continuous observation, the body temperature of pigs in both the experimental and control groups fluctuated within the normal range. Clinical observation revealed that pigs in both groups had normal appetites, no diarrhea, and no deaths; all pigs survived. These data indicate that the porcine rotavirus G1 isolate NM2507 has no significant pathogenicity to weaned piglets.

[0033] Blood and anal swabs were collected from each pig in the challenge group and control group before challenge (day 0) and at 1, 3, 5, 7, and 10 days after challenge. Serum was separated, and viremia and viral shedding were detected by RT-PCR. The results of viremia detection are shown in Table 1. The results of viral shedding detection are shown in Table 2. The data showed that some challenged pigs began to show viremia and viral shedding on day 1, all showed viremia and viral shedding by day 3, and no viremia or viral shedding was observed after day 10.

[0034] Table 1. Results of viremia detection before and after viral challenge.

[0035] Table 2. Pathogen detection results of anal swabs before and after viral challenge.

[0036] The challenge test data showed that the isolate of this invention did not show obvious clinical symptoms after infecting weaned piglets, indicating that it was a low-virulence strain.

[0037] Example 3: Application of isolate NM2507 in the preparation of porcine rotavirus G1 inactivated vaccine 1. Preparation of inactivated vaccine against porcine rotavirus G1 strain The NM2507 isolate was inoculated into MARC-145 or MA104 adherent cells at 1% of the culture volume and passaged continuously. The virus solution was harvested, frozen and thawed once, centrifuged, and the supernatant was collected to determine the virus titer. A virus titer greater than 10 was considered acceptable. 7 TCID 50 / m1, after passing sterility and exogenous virus testing, formaldehyde with a final concentration of 0.2% is added for inactivation.

[0038] Vaccine preparation method: Zhongmu's self-made gelatinous aqueous adjuvant formula: 90% aqueous solution for injection, 3% lacto-hydroxyacetic acid (PLGA), 2% polyvinylpyrrolidone, 2% alkyl glycoside (decyl glucoside) (APG0816), 1% polyethylene glycol 6000, 1% polyoxyethylene sorbitan monooleate, and 1% cetyl alcohol. Wherein, % represents the mass percentage.

[0039] Weigh 9 g of the self-made gelatinous aqueous adjuvant from Zhongmu, mix it with an equal volume of inactivated antigen, and shake thoroughly to mix.

[0040] 2. Vaccine safety trials Six rotavirus-negative piglets (approximately 30 days old) were randomly divided into two groups of three. The experimental group received two doses (4 mL) of inactivated vaccine intramuscularly, followed by a second vaccination 14 days later. The control group received an equal volume of sterile PBS solution intramuscularly, followed by a second PBS vaccination 14 days later. The piglets were observed for 21 consecutive days. Results showed no significant differences in mental state, body temperature, or daily weight gain between the experimental and control groups, and no adverse reactions were observed.

[0041] 3. Vaccine efficacy trials Six weaned piglets that were negative for porcine rotavirus pathogen and antibodies were randomly divided into two groups of three piglets each. The experimental group received one dose (2 mL) of inactivated vaccine intramuscularly, while the control group received an equal volume of sterile PBS solution intramuscularly. The piglets were observed for 35 consecutive days. Blood samples were collected on days 0, 7, 14, 21, 28, and 35. Serum was separated, inactivated at 56℃ for 30 min, and porcine rotavirus G1 neutralizing antibodies were measured. The results of the neutralizing antibody test (as shown in Table 3) indicate that the inactivated vaccine prepared from the strain of this invention, after passage, produced high levels of neutralizing antibodies 28 days after immunization, demonstrating good immunogenicity.

[0042] Table 3. Results of neutralizing antibody detection after inactivated vaccine immunization.

[0043] Example 4: Application of isolate NM2507 in the preparation of an indirect ELISA detection kit 1. Propagate the NM2507 virus isolate for later use.

[0044] NM2507 virus was amplified using MA104 adherent cells. When obvious cytopathic effects appeared in the cells, the virus was harvested and stored at -80°C, undergoing one freeze-thaw cycle. Cell debris was then removed by centrifugation at 6000 r / min for 5 min. The virus was purified using a sucrose density gradient centrifugation method. The purified virus was diluted with PBS, and protein concentration was measured.

[0045] 2. Specific steps of indirect ELISA.

[0046] (1) Coating with whole virus antigen: Purified whole virus was used as the coating antigen. The optimal coating concentration of virus and the optimal serum dilution were determined by serial dilution of antigen and serum using the matrix method. The optimal coating concentration of virus was 3.0 μg / ml, and the optimal coating concentration of virus was 1:100. The purified virus was diluted with coating buffer and coated with 100 μL per well of the ELISA plate, and incubated overnight at 4°C.

[0047] (2) Discard the coating solution, wash 3 times with PBS, add 200 μL of 5% skim milk powder to each well, and block at 37°C for 2 hours. Discard the skim milk, and then wash 3-5 times with PBST for 3-5 minutes each time.

[0048] (3) Dilute the serum to be tested with PBS, then add 100 μL to each well and incubate at 37°C for 1 hour. At the same time, set up negative serum and positive serum controls. Discard the liquid and wash with PBST 3-5 times, 3-5 minutes each time.

[0049] (4) Determine the optimal conditions for the secondary antibody: The optimal dilution of the secondary antibody is 1:10000, and the optimal incubation time is 1 hour. Add 100 μL of diluted horseradish peroxidase-labeled anti-pig IgG secondary antibody to each well and incubate at 37°C for 1 hour. Discard the secondary antibody and wash with PBST 3-5 times, 3-5 minutes each time.

[0050] (5) Add 100 μL of TMB colorimetric solution to each well and develop the color for 10 minutes in the dark.

[0051] (6) Add 50 μL of stop solution (2 M H2SO4) to each well, OD 450 nm reading. Critical value for positive and negative: OD 450 A value ≥ 0.5 nm is considered positive; OD 450 A value less than 0.5 nm indicates a negative result.

[0052] 3. Concordance test between indirect ELISA detection kit and virus neutralization assay Fifteen porcine serum samples were randomly tested using the indirect ELISA kit of this invention. Simultaneous detection was performed using a neutralization assay, as detailed below: Inactivate the serum sample at 56℃ for 30 min. Dilute the serum sample from 1:4 to 1:512, with each dilution performed in triplicate. Add 50 μL to each well, and include positive and negative controls. Add 100 TCID45 to each 50 μL of the diluted serum. 50 The virus solution was added at a rate of 50 μL per well to all wells except the control wells. The mixture was incubated at 37°C with 5% CO2 for 1 h. The solution was then diluted to 3 × 10⁻⁶. 5 / mL~4×10 5 MA104 adherent cell suspension ( / mL) was added to each well after neutralization at a rate of 100 μL. The cells were incubated at 37°C in a 5% CO2 incubator for 48–72 h, and CPE was observed daily. A serum sample showing lesions at a ratio of 1:8 was considered positive; 1:4 was considered suspicious; and <1:4 was considered negative.

[0053] The results of the concordance rate test are shown in Table 4. The results of detecting 15 porcine serum antibodies using the indirect ELISA kit of this invention are consistent with the results of simultaneous detection using the neutralization test, indicating that the method of detecting porcine serum antibodies using the indirect ELISA kit is valid.

[0054] Table 4. Concordance Rate Detection Results between Indirect ELISA Detection Kit and Virus Neutralization Assay

[0055] Note: "+" represents positive; "-" represents negative.

[0056] 4. Sensitivity test of indirect ELISA detection kit Using the three batches of indirect ELISA detection kits (ZM202601~ZM202603) from Example 4, 30 swine serum samples (all wild-type infected serum, provided by China Animal Husbandry Industry Co., Ltd., and inactivated at 56℃ for 30 min) collected from a pig farm were tested according to the usage method described in Example 4. The experimental results are shown in Table 5. The kit of batch ZM202601 detected 29 samples, with a positive detection rate of 96.67% for the 30 serum samples; the kit of batch ZM202602 detected 30 samples, with a positive detection rate of 100.00% for the 30 serum samples; and the kit of batch ZM202603 detected 30 samples, with a positive detection rate of 100.00% for the 30 serum samples.

[0057] Table 5. Sensitivity test results of the indirect ELISA kit. reagent kit batch number Number of detected Positive detection rate ZM202601 29 / 30 96.67% ZM202602 30 / 30 100.00% ZM202603 30 / 30 100.00% 5. Specificity test of indirect ELISA detection kit Using the three batches of indirect ELISA test kits (ZM202601~ZM202603) from Example 4, 20 healthy pig serum samples, 3 classical swine fever virus (CSFV) positive serum samples, 3 porcine reproductive and respiratory syndrome virus (PRRSV) positive serum samples, 3 porcine foot-and-mouth disease virus type O (FMDV-O) positive serum samples, and 3 porcine foot-and-mouth disease virus type A (FMDV-A) positive serum samples were tested according to the usage method described in Example 4.

[0058] The specificity test results of the kits are shown in Table 6 below. The results of testing 20 healthy swine serum samples showed that the specificity of all batches of kits was 100.0%. The test results for 3 positive sera for classical swine fever virus (CSFV), 3 positive sera for porcine reproductive and respiratory syndrome virus (PRRSV), 3 positive sera for porcine foot-and-mouth disease virus type O (FMDV-O), and 3 positive sera for porcine foot-and-mouth disease virus type A (FMDV-A) were all negative. Therefore, the specificity of all three batches of kits for detecting these 12 positive sera for related pathogens was 100%.

[0059] Table 6. Specificity detection results of the indirect ELISA assay kit

[0060] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.

Claims

1. A porcine rotavirus G1 strain, characterized by: The porcine rotavirus G1 strain is named NM2507, classified as porcine rotavirus, and its accession number at the China General Microbiological Culture Collection Center is CGMCC No. 47090.

2. The porcine rotavirus G1 strain according to claim 1, characterized in that: The VP7 gene sequence of the porcine rotavirus G1 strain is shown in Sequence 1 of the sequence listing.

3. A biological product containing the porcine rotavirus G1 strain as described in claims 1 and 2, said biological product being used for the prevention or diagnosis of viral diseases caused by porcine rotavirus G1.

4. The biological product according to claim 3, characterized in that: The biological products mentioned are vaccines or diagnostic reagents.

5. The biological product according to claim 4, characterized in that: The vaccine is either a live vaccine or an inactivated vaccine, and the vaccine also includes a pharmaceutically acceptable adjuvant.

6. The biological product according to claim 4, characterized in that: The diagnostic reagent is an ELISA kit, which includes an enzyme-labeled plate coated with the whole virus of porcine rotavirus CGMCC No. 47090 and an enzyme-labeled secondary antibody.

7. The use of the porcine rotavirus G1 strain according to claims 1 and 2 in the preparation of a vaccine for the prevention of viral diseases caused by porcine rotavirus G1.

8. The use of the porcine rotavirus G1 strain according to claims 1 and 2 in the preparation of reagents for diagnosing viral diseases caused by porcine rotavirus G1.

Images